MW151 / Immunochem Therap - LARVOL DELTA

MW151-102: MW151 and Whole-brain Radiotherapy in Patients with Intracranial Metastases (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: ImmunoChem Therapeutics, LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Jul 2025

Enrollment closed • Trial completion date • CNS Disorders • Cognitive Disorders • Developmental Disorders • Oncology

MW151-102: MW151 and Whole-brain Radiotherapy in Patients With Intracranial Metastases (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: ImmunoChem Therapeutics, LLC | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jul 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Developmental Disorders • Oncology

MW151-102: MW151 and Whole-brain Radiotherapy in Patients With Intracranial Metastases (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: ImmunoChem Therapeutics, LLC | Trial completion date: Aug 2024 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Jul 2024

Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Developmental Disorders • Oncology

MW151-102: MW151 and HA-WBRT in Patients With Brain Metastases (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: ImmunoChem Therapeutics, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Cognitive Disorders • Developmental Disorders • Oncology • Solid Tumor

MW151-102: MW151 and HA-WBRT in Patients With Brain Metastases (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: ImmunoChem Therapeutics, LLC

New P1 trial • CNS Disorders • Cognitive Disorders • Developmental Disorders • Oncology • Solid Tumor

Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology. (PubMed, PLoS One) - "We found that MW151 was able to partially rescue hippocampal-dependent spatial memory and learning deficits in this comorbidity context, and further, that the benefit is associated with a normalization of hippocampal metabolites detectable via magnetic resonance spectroscopy. These findings provide evidence that MW151 in particular, and potentially anti-inflammatory treatment more generally, may be beneficial in AD patients with comorbid vascular pathology."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Metabolic Disorders

Exploring cell signaling pathways engaged by two novel small molecule drug candidates (MW151 and MW189) that selectively modulate stressor-induced neuroinflammation (Neuroscience 2021) - P1a, P1b | "While these findings offer intriguing clues, an unbiased proteomic exploration of BV-2 cells exposed to MW151 and MW189 is being undertaken to more clearly identify the molecular mechanism(s) and target pathway(s) of these drugs. Successful identification of the signaling pathways and proteins modulated by MW151 and MW189 in vitro will provide the biological rationale for design of future clinical trials, and possibly open new avenues of exploration in future drug development programs."

CNS Disorders • IL6

MW151-101: First-in-human Study of MW151 (clinicaltrials.gov) - P1a; N=40; Completed; Sponsor: Linda Van Eldik; Recruiting ➔ Completed

Clinical • Trial completion

MW151-101: First-in-human Study of MW151 (clinicaltrials.gov) - P1a; N=40; Recruiting; Sponsor: Linda Van Eldik; Trial completion date: Jan 2021 ➔ Nov 2021; Trial primary completion date: Jan 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date

MW151-101: First-in-human Study of MW151 (clinicaltrials.gov) - P1a; N=40; Recruiting; Sponsor: Linda Van Eldik; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open